Low Levels of Urinary PSA Better Identify Prostate Cancer Patients

• Main Authors: Sergio Occhipinti, Giulio Mengozzi, Marco Oderda, Andrea Zitella, Luca Molinaro, Francesco Novelli, Mirella Giovarelli, Paolo Gontero
• Format: Article
• Language: English
• Published: MDPI AG 2021-07-01
• Series: Cancers
• Subjects: prostate cancer prevention; prostate cancer detection; screening; biomarkers; diagnosis; early detection
• Online Access: https://www.mdpi.com/2072-6694/13/14/3570

Serum prostatic specific antigen (PSA) has proven to have limited accuracy in early diagnosis and in making clinical decisions about different therapies for prostate cancer (PCa). This is partially due to the fact that an increase in PSA in the blood is due to the compromised architecture of the prostate, which is only observed in advanced cancer. On the contrary, PSA observed in the urine (uPSA) reflects the quantity produced by the prostate, and therefore can give more information about the presence of disease. We enrolled 574 men scheduled for prostate biopsy at the urology clinic, and levels of uPSA were evaluated. uPSA levels resulted lower among subjects with PCa when compared to patients with negative biopsies. An indirect correlation was observed between uPSA amount and the stage of disease. Loss of expression of PSA appears as a characteristic of prostate cancer development and its evaluation in urine represents an interesting approach for the early detection of the disease and the stratification of patients.